Lung Cancer Diagnostic and Screening Market Analysis & Forecast: 2026-2033
Lung Cancer Diagnostic and Screening Market is estimated to be valued at USD 3,287.8 Mn in 2026 and is expected to reach USD 6,530.4 Mn in 2033, exhibiting a compound annual growth rate (CAGR) of 10.3% from 2026 to 2033. The lung cancer diagnostic and screening market is witnessing strong transformation driven by early detection mandates and advanced imaging technologies such as low-dose CT (LDCT), which the USPSTF reaffirmed in March 2021 for adults aged 50–80 years with a ≥20 pack-year smoking history and reported ~20% mortality reduction in high-risk populations through screening programs. CDC guidelines (October 2024) further confirm eligibility expansion to current or former smokers within 15 years. According to WHO cancer updates (February 2024), lung cancer remains the leading cause of cancer death globally, reinforcing demand for screening. In 2026, AI-based nodule detection systems and liquid biopsy innovations are accelerating precision diagnostics, improving early-stage detection rates and clinical decision-making efficiency across healthcare systems worldwide.
(Source: USPSTF Lung Cancer Screening Recommendation; CDC; WHO)
(Source: CDC; Cancer.org; Medicare.gov; CDC; UCONN.Edu)
Imaging Test is projected to account for the largest share in 2026, representing approximately 45.2% of the total volume. Imaging tests dominate the lung cancer diagnostic and screening market due to their role as the first-line detection method for early-stage tumors and lung nodules. Low-dose CT and PET-CT offer high sensitivity, enabling early identification before symptoms appear. Strong government-backed screening programs and clinical guidelines from CDC and WHO further reinforce imaging as the primary diagnostic pathway in hospitals. For instance, CDC (Updated May 2026) states that the recommended lung cancer screening test is low-dose CT (LDCT) for high-risk individuals, confirming CT as the standard first-line screening modality in the U.S. The U.S. Preventive Services Task Force (USPSTF, reaffirmed guideline 2025–2026 updates) recommends annual LDCT screening for adults aged 50–80 with ≥20 pack-year smoking history, covering the entire high-risk population eligible for screening. The USPSTF evidence base shows LDCT screening provides a ~20% reduction in lung cancer mortality compared with chest X-ray screening (National Lung Screening Trial evidence used in guidelines).
Based on cancer type, Non-Small Cell Lung Cancer (NSCLC) dominate the market, accounting for a significant 80.0% share in 2026. The non-small cell lung cancer (NSCLC) segment is dominant because it represents the largest case pool, creating higher need for screening, biopsy confirmation, molecular profiling, and follow-up imaging. The American Cancer Society notes that NSCLC accounts for about 80%–85% of lung cancers, while its January 2026 statistics estimated 229,410 new U.S. lung and bronchus cancer cases and 124,990 deaths in 2026. This large burden keeps hospitals focused on NSCLC detection pathways, especially adenocarcinoma and squamous cell carcinoma. Imaging remains dominant because CDC, published May 2026, states low-dose CT is the recommended lung cancer screening test for early detection in practice.
(Source: American Cancer Society; CDC lung cancer screening guidance, published May 2026; cancer.org)
To learn more about this report, Request Free Sample
Hospital associated labs dominate the global lung cancer diagnostic and screening market with the share of 46.8% because hospitals integrate radiology, pathology, oncology, biopsy, and molecular testing under one clinical workflow. The American Cancer Society, published in January 2026, estimated 229,410 new lung and bronchus cancer cases and 124,990 deaths in the U.S., supporting high hospital diagnostic volume. CDC, published in May 2026, stated that low-dose CT is the recommended screening test for high-risk adults aged 50–80 with 20 pack-year history, and only about 18% of eligible adults were screened. This makes imaging dominant, as hospital-based LDCT, CT, and PET-CT trigger follow-up biopsy and laboratory confirmation.
Increasing Research & Development activities for early detection of cancer are expected to propel the growth of the global lung cancer diagnostic and screening market over the forecast period. For instance, in April 2020, researchers at the Massachusetts Institute of Technology (MIT) developed a nanoparticle-based approach that allows the early diagnosis of lung cancer through a simple urine test. The strategy detects biomarkers resulting from the interaction of peptide-coated nanoparticles with disease-associated proteases in the tumor microenvironment. Experiments in two different mouse models of lung cancer showed that the urine test could detect tumors as small as 2.8 mm. The researchers hope that this type of noninvasive diagnosis could reduce the number of false positives associated with an existing test method and help to detect more tumors in the early stages of the disease.
Expansion of LDCT screening programs and AI-based nodule detection & risk stratification are the major factors creating the opportunity for the growth of the global lung cancer diagnostic and screening market over the forecast period. Low-dose CT remains the recommended screening test for lung cancer, creating strong demand for imaging centers, CT systems, radiology services, and screening workflow solutions. CDC updated its lung cancer screening page in May 2026, confirming LDCT as the recommended screening method. Furthermore, AI tools can help radiologists prioritize suspicious lung nodules, reduce missed findings, and improve diagnostic decision-making. For instance, in April 2026, Coreline Soft reported that Germany’s national low-dose CT lung cancer screening program requires mandatory AI-assisted detection software to ensure standardized, high-quality diagnosis workflows. The guideline mandates CE-marked, MDR-compliant CAD systems with PACS/RIS integration, supporting dual-reading interpretation and structured reporting across screening centers. Framework emphasizes GDPR compliance, interoperability, and consistent nodule detection performance, positioning AI as a core infrastructure component in nationwide lung cancer screening implementation in system.
|
Current Event |
Description and its Impact |
|
Australia National Lung Cancer Screening Program Launch |
|
|
NHS Lung Cancer Screening Programme Rollout in England |
|
|
EU Cancer Screening Funding and Lung Cancer Screening Pilots; |
|
|
FDA Approval of Targeted NSCLC Therapy Linked to FDA-Authorized Testing |
|
|
European Cancer Imaging Initiative and AI-Enabled Screening Infrastructure |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Increasing awareness campaigns to increase the number of diagnostic and screening tests for lung cancer are expected to drive the growth of the global lung cancer diagnostic and screening market over the forecast period. For instance, in November 2022, the government of Canada initiated Lung Cancer Awareness Month to raise awareness about lung cancer and the actions to help prevent it and reduce the stigma associated with this disease.
Government-led LDCT screening programs are expanding globally, making imaging the backbone of early lung cancer detection. These programs focus on high-risk populations (smokers aged 50–80) to identify lung nodules before symptoms appear. For example, the CDC (May 2026) confirms LDCT as the only recommended screening test in the U.S., while Australia’s national program (2025 rollout continuing into 2026) covers high-risk individuals using mobile CT units, significantly increasing screening penetration.
AI-based radiology tools are increasingly integrated into CT and PET-CT workflows to improve accuracy in detecting small lung nodules and reduce diagnostic delays. In 2026, European Cancer Imaging Initiative projects expanding AI training datasets to over 60 million imaging records, enabling better algorithm validation. Hospitals are adopting AI triage systems that prioritize high-risk scans, improving early detection efficiency and reducing radiologist workload in lung cancer screening programs.
Liquid biopsy is gaining momentum as a non-invasive complement to imaging, especially for NSCLC molecular profiling. The U.S. FDA (February 2026) approved targeted therapies such as HER2-directed treatments requiring FDA-authorized diagnostic testing, increasing demand for biomarker assays. This trend is expanding the role of hospital laboratories, where ctDNA, NGS panels, and blood-based tests are increasingly used alongside imaging for precision oncology decision-making.
Hospitals are becoming centralized hubs combining imaging, pathology, and molecular testing under one workflow. CDC data (May 2026) indicates only ~18% screening uptake in eligible U.S. populations, pushing hospitals to expand diagnostic capacity. Integrated cancer centers ensure that LDCT screening immediately flows into biopsy and molecular testing, improving diagnostic speed and increasing hospital associated lab dominance in the global market.
Governments and global health bodies are increasing funding for lung cancer early detection programs. The WHO (2026 updates) continues to emphasize lung cancer as the leading cause of cancer mortality globally, driving policy action toward screening expansion. EU4Health and national programs in the UK and EU are investing in population-based screening pilots, boosting demand for CT infrastructure, diagnostic labs, and oncology imaging services across hospitals.
To learn more about this report, Request Free Sample
North America is estimated to hold 33.5% of the market share in 2026. The global lung cancer diagnostic and screening market is expected to witness significant growth in the coming years, driven by the high prevalence of lung cancer. The increasing prevalence of neurological disorders is contributing to the growth of the lung cancer diagnostic and screening market in the North America region. For instance, according to data published by the American Society of Clinical Oncology (ASCO) on March 3, 2023, worldwide, lung cancer is the second most commonly diagnosed cancer, while NSCLC (non-small cell lung cancer) is the most common type of lung cancer in the U.S., accounting for 81% of all lung cancer diagnoses.
Asia-Pacific is the fastest-growing region in the lung cancer diagnostic and screening market because the region carries a large undiagnosed patient pool, high smoking and air-pollution exposure, aging populations, and expanding national screening capacity. WHO, updated April 2026, reported lung cancer as the leading cancer, with 2.5 million cases and 1.8 million deaths globally, and linked most preventable cases to tobacco, air pollution, and occupational exposure. In February 2026, India’s PIB said early detection is a major lung cancer challenge and released national evidence-based guidelines to strengthen diagnosis pathways. In April 2026, ASCO Post reported China’s LUNG-CARE study of nearly 12,000 adults, where LDCT screening raised stage-I detection to 81.5% versus 25.1%, supporting wider CT screening adoption.
The U.S. dominates the North America lung cancer diagnostic and screening market due to its high disease burden, structured screening guidelines, advanced hospital imaging capacity, and rapid adoption of precision diagnostics. The American Cancer Society, published in January 2026, estimated 229,410 new lung cancer cases and 124,990 deaths in the U.S., creating strong diagnostic demand. CDC, updated in May 2026, states that low-dose CT is the recommended screening test for high-risk adults and that only about 18% of eligible U.S. adults were screened, leaving major room for screening expansion. This supports imaging dominance, as LDCT is the first-line detection tool. In February 2026, the U.S. FDA approved zongertinib for HER2-mutated NSCLC detected by an FDA-authorized test, boosting biomarker testing adoption.
Some of the major key players in Lung Cancer Diagnostic and Screening Market are Abbott, Amgen Inc., Illumina, Inc., Thermo Fisher Scientific Inc., Lepu Medical Technology (Beijing)Co.,Ltd., AstraZeneca, F. Hoffmann-La Roche Ltd, Laboratory Corporation of America Holdings., Agilent Technologies, Inc., QIAGEN, Quest Diagnostics Incorporated., NeoGenomics Laboratories., Myriad Genetics, Inc., GRAIL, LLC., DELFI Diagnostics.
(Source: Qure.ai)
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 3,287.8 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 10.3% | 2033 Value Projection: | USD 6,530.4 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Abbott, Amgen Inc., Illumina, Inc., Thermo Fisher Scientific Inc., Lepu Medical Technology (Beijing)Co.,Ltd., AstraZeneca, F. Hoffmann-La Roche Ltd, Laboratory Corporation of America Holdings., Agilent Technologies, Inc., QIAGEN, Quest Diagnostics Incorporated., NeoGenomics Laboratories., Myriad Genetics, Inc., GRAIL, LLC., DELFI Diagnostics. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Major players operating in the global lung cancer diagnostic and screening market include Abbott, Amgen Inc., Illumina, Inc., Thermo Fisher Scientific Inc., Lepu Medical Technology (Beijing)Co.,Ltd., AstraZeneca, F. Hoffmann-La Roche Ltd, Laboratory Corporation of America Holdings., Agilent Technologies, Inc., QIAGEN, Quest Diagnostics Incorporated., NeoGenomics Laboratories., Myriad Genetics, Inc., GRAIL, LLC., and DELFI Diagnostics.
Lung cancer is a disease caused by uncontrolled cell division in the lungs. The rising number of patient population with lung cancer is expected to increase the diagnosis and screening of lung cancer. Thus, it offers the opportunity for various manufacturers to offer innovative lung cancer diagnostic and screening methods that allow for early detection of lung cancer.
Definition: Lung cancer screening is a process that's used to detect the presence of lung cancer in otherwise healthy people with a high risk of lung cancer. Lung cancer screening is recommended for older adults who are longtime smokers and who don't have any signs or symptoms of lung cancer.
Share
Share
Manisha Vibhute is a consultant with over 5 years of experience in market research and consulting. With a strong understanding of market dynamics, Manisha assists clients in developing effective market access strategies. She helps medical device companies navigate pricing, reimbursement, and regulatory pathways to ensure successful product launches.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
